title: Tyrosine kinase inhibitor therapy for systemic sclerosis: Quo Vadis?
authors.forename: Fabian A
authors.initials: FA
authors.lastname: Mendoza
authors.forename: Sergio A
authors.initials: SA
authors.lastname: Jiménez
mesh_terms: D001549:Benzamides; D057239:Early Termination of Clinical Trials; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D017563:Lung Diseases, Interstitial / Q000188:drug therapy*; D008297:Male; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use*; D045743:Scleroderma, Diffuse / Q000188:drug therapy*; D012595:Scleroderma, Systemic / Q000150:complications*
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate